Sign In
Buy XBI
$159.03
-5.25 (-3.20%)
At Close: Jul 10, 2026
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
02:47pm, Thursday, 09'th Jul 2026
Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in Inve
Stocks Look Shaky, But This Sector is Booming (Biotech)
02:06pm, Thursday, 09'th Jul 2026
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
This ETF Is Up Nearly 17% in a Month and Doesn't Own a Single Share of Nvidia
12:50pm, Monday, 06'th Jul 2026
Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over the trailing month ending July 1, 2026, a run that would look right at home
June's Top ETFs: Biotech & China Semiconductors Surge
12:12pm, Wednesday, 01'st Jul 2026
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out
Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It
05:00pm, Monday, 29'th Jun 2026
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
12:11pm, Monday, 29'th Jun 2026
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A
04:34pm, Tuesday, 23'rd Jun 2026
The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
07:20am, Tuesday, 23'rd Jun 2026
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched
Wall Street Technician Declares Financials, Industrials, and Biotech Poised for Breakouts. 3 ETFs Could Soar.
10:05am, Saturday, 20'th Jun 2026
Markets are hunting for new leadership as the Big Tech engine sputters, and one Wall Street technician thinks she knows where the baton is being passed.
XBI: A "Hidden" ETF Up +70% In 1 Year.
09:40am, Saturday, 20'th Jun 2026
State Street SPDR S&P Biotech ETF (XBI) has delivered over 75% 1-year performance, driven by equal-weight exposure to volatile small- and mid-cap biotech stocks. XBI's high beta profile offers strong
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?
03:46pm, Wednesday, 17'th Jun 2026
iShares U.S. Pharmaceuticals ETF offers a significantly higher dividend yield and lower volatility than State Street SPDR S&P Biotech ETF. While State Street SPDR S&P Biotech ETF delivered stronger 1-
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
01:00am, Tuesday, 16'th Jun 2026
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-trac
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
3 Longevity ETFs to Buy and Hold (and Hold)
07:40am, Monday, 08'th Jun 2026
Longevity is, increasingly, a big business. Advances in healthcare technology and AI have prompted both prominent medical professionals and individual investors to imagine how people might live longer
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
08:45am, Friday, 05'th Jun 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
